Restricted accessEditorialFirst published online 2000-06
Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure
The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325:293-302.
2.
The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med1992;327:685-91.
3.
Pfeffer MM, Braunwald E., Moye Lemuel A. et al. On Behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med1992;327:669-77.
4.
Rousseau MF, Konstam MA, Benedict Claude R. et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor . Am J Cardiol1994;73:488-93.
5.
MacFadyen RJ , Lee AF, Morton JJ, Pringle SD, Struthers AD: How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure ? Heart1999;82(1):57-61.
6.
Van den Meiracker AH, Man in `t Veld, PJ, Ritesma van Eck HJ, BoomsmaF, Derkx FH, Schalekamp. MA Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?J Hypertens1992; 10(8):803-12.
7.
Brunner-La Rocca HP, Vaddadi Gautm, Esler MDRecent insight into therapy of congestive heart failure: Focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol1993;33:1163-73.
8.
Pitt Bertram , Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the losartan heart failure survival study-Elite II. J Cardiac Failure1999;5:146-52.
9.
Pitt B., Poole-Wilson P., Segal R. et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure - Elite II. Lancet2000 (In press).
10.
Christen Y.Waeber B., Nussberger J. et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation1991; 83:1333-42.
11.
Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation1999;99:990-2.
12.
Baruch L.,Anand I., Cohen IS, Ziesche S., Judd D., Cohn JNFor the Vasodilator Heart Failure Trial (V-Heft) study Group: Augmented short - and long term haemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation1999;99:2658-64.
13.
Benard J., Campbell DJ, Azizi M., Gonzales MFSynergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation1997;96:3072-8.
McKelvie RS , Yusuf S., Pericak et al. Comparision of candesartan, enalapril, and their combination in congestive heart failure: randomised evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators . Circulation1999;100:1056-64.
16.
Murdoch DR, McDonagh TA, Byrne J. et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomised comparison of the haemodynamic and neuroendocrine effects of tailored versus empirical therapy . Am Heart J1990;138(6): 1126-32.
17.
Jorde UP, Ennezat PV, Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation2000 ;101(8):844-6.
18.
Dell'Italia LJ, Meng QC, Balcells E. et al. Compartmentalization of angiotensin II generation in the dog heart: evidence for independent mechanisms in intravascular and interstitial spaces.J Clin Invest1997 ;100:253-8.
19.
Muller P., Cohen T., DeGasparo M., Sioufi A., Racine-Poon A., Howald H.Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol1994;47:231-45.
20.
Wollert Kai C., Studer Roland, Bodil von Bulow BS, Drexler H.Survival after myocardial infarction in the rat-role of tissue angiotensin-converting enzyme inhibition. Circulation1994;90:2457-67.
21.
Roig E., Perez-Villa F., Morales M. et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J2000;21(1):53-7.
